Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
The article describes a clinical case of ALK-positive non-small cell lung cancer and its long-term treatment with a chemotherapy drug pemetrexed as first-line regimen followed by pemetrexed maintenance therapy.
Main Authors: | A. M. Lozhkina, M. A. Sviridenko, A. O. Cheremnykh, E. A. Filippova, M. A. Urtenova, S. V. Odintsova, S. V. Orlov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-11-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2749 |
Similar Items
-
Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
by: Joon‐Young Yoon, et al.
Published: (2019-04-01) -
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
by: Takashi Kasai, et al.
Published: (2023-07-01) -
Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
by: Wei-Jing Gong, et al.
Published: (2022-05-01) -
Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01) -
Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
by: Jieun Yang, et al.
Published: (2022-04-01)